G-CSF is a glycoprotein that stimulates the production of stem cells and granulocytes in the bone marrow and then releases them into the bloodstream. G-CSF is produced by different of tissues, and its pharmacological analogues include filgrastim and lenograstim. G-CSF also stimulates survival, proliferation, differentiation, and function of mature & neutrophil precursors. G-CSF has several applications in haematology and oncology; for example, a recombinant form of G-CSF is used with some cancer patients to reduce mortality and speed recovery from neutropenia after chemotherapy, allowing for higher-intensity treatment regimens.
The "Global Granulocyte-Colony Stimulating Factor Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the granulocyte-colony stimulating factor market with detailed market segmentation by drug product and application. The report provides key statistics on the market status of the leading granulocyte-colony stimulating factor market players and offers key trends and opportunities in the market.
- Based on product the market is segmented as, tablet, capsule and others.
- On the basis of application the market is classified oncology, blood disorder, acute and chronic diseases and growth hormone diseases and others.
- Growing prevalences of cancers and other chronic disorders.
- Advancements and developments in genomics technology and healthcare are expected to spur the market growth during the forecast period.
- Ongoing R&D activities to develop therapies for management of maliganancies and their complications.
- However, high cost the treatment and possibility of other side effects may restrain market growth during the forecast period.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The granulocyte-colony stimulating factor market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the granulocyte-colony stimulating factor market in these regions.
IMPACT OF COVID-19 ON GRANULOCYTE-COLONY STIMULATING FACTOR MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. Due to restrictions and lockdowns imposed there is a big shift in the cancer treatment as people cannot go out for their treatments which is affecting the market growth of granulocyte-colony stimulating factor agents. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
The report covers key developments in the granulocyte-colony stimulating factor market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from granulocyte-colony stimulating factor market are anticipated to lucrative growth opportunities in the future with the rising demand for granulocyte-colony stimulating factor in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the granulocyte-colony stimulating factor market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Intas Pharmaceuticals Ltd
- Sandoz Inc
- Amgen Inc
- Teva Pharmaceutical Industries Ltd
- STADA Arzneimittel AG
- Novartis AG
- Pfizer Inc
- Dr. Reddy's Laboratories Ltd
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.